Artikel baru tentang topik farmasi yang masih memerlukan tambahan dan pengembangan. Artikel ini merupakan terjemahan wikipedia bahasa Inggris masih perlu ditinjau ulang juga disesuaikan dengan padanan bahasa Indonesia
<!-- Chemical and physical data -->|C=29|H=41|N=1|O=4|smiles=Oc7ccc5c1c7O[C@H]3[C@]6(OC)[C@H](C[C@@]2([C@H](N(CC[C@@]123)CC4CC4)C5)CC6)[C@@](O)(C)C(C)(C)C|StdInChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1|StdInChI_Ref={{stdinchicite|correct|chemspider}}|StdInChIKey=RMRJXGBAOAMLHD-IHFGGWKQSA-N|StdInChIKey_Ref={{stdinchicite|correct|chemspider}}}}
'''Buprenorfin''' (Buprenorphine), adalah obat golongan opioid yang digunakan untuk mengatasi gangguan penggunaan opioid, [[nyeri]] akut, dan [[Sakit kronis|nyeri kronis]]. <ref name="ASHP2017">{{Cite web|title=Buprenorphine Hydrochloride|url=https://www.drugs.com/monograph/buprenorphine-hydrochloride.html|website=drugs.com|publisher=American Society of Health-System Pharmacists|access-date=17 March 2017|date=26 January 2017|archive-date=18 July 2017|archive-url=https://web.archive.org/web/20170718164516/https://www.drugs.com/monograph/buprenorphine-hydrochloride.html|url-status=live}}</ref> Rute pemberian obat bisa digunakan di bawah lidah, di pipi, melalui [[injeksi]], sebagai [[plester transdermal]], atau sebagai [[implan]]. <ref name="ASHP2017">{{cite web|title=Buprenorphine Hydrochloride|url=https://www.drugs.com/monograph/buprenorphine-hydrochloride.html|website=drugs.com|publisher=American Society of Health-System Pharmacists|access-date=17 March 2017|date=26 January 2017|archive-date=18 July 2017|archive-url=https://web.archive.org/web/20170718164516/https://www.drugs.com/monograph/buprenorphine-hydrochloride.html|url-status=live}}</ref> <ref>{{Cite web|title=Press Announcements – FDA approves first buprenorphine implant for treatment of opioid dependence|url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm503719.htm|website=FDA|language=en|archive-url=https://web.archive.org/web/20171130112207/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm503719.htm|archive-date=30 November 2017|access-date=12 December 2017|url-status=live}}</ref>. Formulasi kombinasi buprenorfin, dan [[nalokson]] (Suboxone) direkomendasikan untuk subtitusi dariuntuk pecandu narkoba, jugadan digunakan secara injeksi. <ref name="ASHP2017">{{cite web|title=Buprenorphine Hydrochloride|url=https://www.drugs.com/monograph/buprenorphine-hydrochloride.html|website=drugs.com|publisher=American Society of Health-System Pharmacists|access-date=17 March 2017|date=26 January 2017|archive-date=18 July 2017|archive-url=https://web.archive.org/web/20170718164516/https://www.drugs.com/monograph/buprenorphine-hydrochloride.html|url-status=live}}</ref> Sedangkan untuk terapi pereda nyeri pada obat ini digunakan secara maksimal, dan hanya dalam waktu satu jam dengan efek terapi bertahan hingga 24 jam. <ref name="ASHP2017">{{cite web|title=Buprenorphine Hydrochloride|url=https://www.drugs.com/monograph/buprenorphine-hydrochloride.html|website=drugs.com|publisher=American Society of Health-System Pharmacists|access-date=17 March 2017|date=26 January 2017|archive-date=18 July 2017|archive-url=https://web.archive.org/web/20170718164516/https://www.drugs.com/monograph/buprenorphine-hydrochloride.html|url-status=live}}</ref>
